These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 17532631

  • 21. Synthesis and biological evaluation of novel alkyl amide functionalized trifluoromethyl substituted pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents.
    Chavva K, Pillalamarri S, Banda V, Gautham S, Gaddamedi J, Yedla P, Kumar CG, Banda N.
    Bioorg Med Chem Lett; 2013 Nov 01; 23(21):5893-5. PubMed ID: 24060486
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD.
    Bioorg Med Chem; 2007 Sep 01; 15(17):5837-44. PubMed ID: 17601739
    [Abstract] [Full Text] [Related]

  • 23. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    Hassan GS, Georgey HH, Mohammed EZ, George RF, Mahmoud WR, Omar FA.
    Eur J Med Chem; 2021 Jun 05; 218():113389. PubMed ID: 33784602
    [Abstract] [Full Text] [Related]

  • 24. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
    Li J, Zhao YF, Zhao XL, Yuan XY, Gong P.
    Arch Pharm (Weinheim); 2006 Nov 05; 339(11):593-7. PubMed ID: 17036367
    [Abstract] [Full Text] [Related]

  • 25. Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
    Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, Keertikar K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann TO, Hruza A, Madison V, Nomeir AA, Wang Y, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6220-3. PubMed ID: 17904841
    [Abstract] [Full Text] [Related]

  • 26. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S, Li R, Connolly PJ, Emanuel S, Middleton SA.
    Bioorg Med Chem Lett; 2006 Sep 15; 16(18):4818-21. PubMed ID: 16870444
    [Abstract] [Full Text] [Related]

  • 27. Cancerostatica. I. synthesis of some pyrazolo[1,5-a]pyrimidine and pyrazolo [3,4-b] pyridine derivatives.
    Nantka-Namirski P, Kaczmarek L.
    Pol J Pharmacol Pharm; 1978 Sep 15; 30(4):563-8. PubMed ID: 740557
    [Abstract] [Full Text] [Related]

  • 28. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
    Liu JJ, Daniewski I, Ding Q, Higgins B, Ju G, Kolinsky K, Konzelmann F, Lukacs C, Pizzolato G, Rossman P, Swain A, Thakkar K, Wei CC, Miklowski D, Yang H, Yin X, Wovkulich PM.
    Bioorg Med Chem Lett; 2010 Oct 15; 20(20):5984-7. PubMed ID: 20832307
    [Abstract] [Full Text] [Related]

  • 29. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Saavedra O, Claridge S, Zhan L, Raeppel F, Granger MC, Raeppel S, Mannion M, Gaudette F, Zhou N, Isakovic L, Bernstein N, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Wang J, Macleod AR, Besterman JM, Vaisburg A.
    Bioorg Med Chem Lett; 2009 Dec 15; 19(24):6836-9. PubMed ID: 19896842
    [Abstract] [Full Text] [Related]

  • 30. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
    Lee J, Kim KH, Jeong S.
    Bioorg Med Chem Lett; 2011 Jul 15; 21(14):4203-5. PubMed ID: 21684737
    [Abstract] [Full Text] [Related]

  • 31. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
    Park A, Hwang J, Lee JY, Heo EJ, Na YJ, Kang S, Jeong KS, Kim KY, Shin SJ, Lee H.
    Bioorg Med Chem Lett; 2021 Sep 01; 47():128226. PubMed ID: 34182093
    [Abstract] [Full Text] [Related]

  • 32. Facile synthesis and in-vitro antitumor activity of some pyrazolo[3,4-b]pyridines and pyrazolo[1,5-a]pyrimidines linked to a thiazolo[3,2-a]benzimidazole moiety.
    Abdel-Aziz HA, Saleh TS, El-Zahabi HS.
    Arch Pharm (Weinheim); 2010 Jan 01; 343(1):24-30. PubMed ID: 19921685
    [Abstract] [Full Text] [Related]

  • 33. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R, Johnson SG, Connolly PJ, Wetter SK, Binnun E, Hughes TV, Murray WV, Pandey NB, Moreno-Mazza SJ, Adams M, Fuentes-Pesquera AR, Middleton SA.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2333-7. PubMed ID: 19286381
    [Abstract] [Full Text] [Related]

  • 34. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.
    Lukasik PM, Elabar S, Lam F, Shao H, Liu X, Abbas AY, Wang S.
    Eur J Med Chem; 2012 Nov 15; 57():311-22. PubMed ID: 23085105
    [Abstract] [Full Text] [Related]

  • 35. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1844-53. PubMed ID: 20153204
    [Abstract] [Full Text] [Related]

  • 36. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2969-74. PubMed ID: 21470862
    [Abstract] [Full Text] [Related]

  • 37. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z, Perretta C, Erickson P, Margosiak S, Lu J, Averill A, Almassy R, Chu S.
    Bioorg Med Chem Lett; 2008 Jan 15; 18(2):619-23. PubMed ID: 18055206
    [Abstract] [Full Text] [Related]

  • 38. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
    Le Brazidec JY, Pasis A, Tam B, Boykin C, Black C, Wang D, Claassen G, Chong JH, Chao J, Fan J, Nguyen K, Silvian L, Ling L, Zhang L, Choi M, Teng M, Pathan N, Zhao S, Li T, Taveras A.
    Bioorg Med Chem Lett; 2012 Mar 01; 22(5):2070-4. PubMed ID: 22326168
    [Abstract] [Full Text] [Related]

  • 39. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I, Albert DH, Bousquet PF, Cunha GA, Harris CM, Moskey M, Dinges J, Stewart KD, Sowin TJ.
    Bioorg Med Chem Lett; 2007 Jun 01; 17(11):3136-40. PubMed ID: 17391959
    [Abstract] [Full Text] [Related]

  • 40. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
    Zhu GD, Gong J, Claiborne A, Woods KW, Gandhi VB, Thomas S, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Stoll VS, De Jong R, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3150-5. PubMed ID: 16603355
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.